Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase 2 blinded biomarker validation and panel discovery study - PubMed
5 hours ago
- #early detection
- #biomarkers
- #pancreatic cancer
- The Pancreatic Cancer Detection Consortium (PCDC) conducted a phase 2 blinded biomarker validation study to evaluate blood-based biomarker panels for pancreatic cancer detection.
- The study involved 140 stage I-IV pancreatic cancer cases and 140 controls, with samples including plasma, serum, and germline DNA.
- Ten biomarkers representing eight panels were evaluated, with CA19-9 alone serving as a comparator.
- Two panels outperformed CA19-9 alone: the CA19-9/FUT2/3 panel (AUC=96.3) and the TFPI/TNC-FNIII-C panel (AUC=95).
- Exploratory models using LASSO regression retained most biomarkers, achieving an optimism-corrected AUC of 96.4.
- The study concludes that the CA19-9/FUT2/3 panel is the top performer, warranting further evaluation in larger studies.
- The PCDC recommends biomarker bakeoffs as an effective strategy for comparing pancreatic cancer early detection biomarkers.